The city of Nashville, Tennessee, currently has 16 active clinical trials seeking participants for Parkinson's Disease research studies.
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Recruiting
The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
06/19/2024
Locations: Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Parkinson's Disease
Quantitation of Glymphatic Functioning in Sleep and Meditative States
Recruiting
This involves development and application of magnetic resonance imaging (MRI) methods for visualizing hemodynamic and metabolic relationships in healthy volunteers with advanced meditation experience.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/29/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease, Sleep
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Recruiting
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
02/27/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis